Trial reportDiabetes2014
Acute administration of unacylated ghrelin has no effect on Basal or stimulated insulin secretion in healthy humans.
Trial report in Diabetes, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02690987 (Do Appetitive Gut Hormones Reduce Addictive and Eating Behaviours in Obesity, and Nicotine and Alcohol Dependence?), which is not on this map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Do Appetitive Gut Hormones Reduce Addictive and Eating Behaviours in Obesity, and Nicotine and Alcohol Dependence?
Who cites it
25 citing papers in PubMed, 47 citations in OpenAlex.
- Effect of ghrelin on glucose tolerance, gut hormones, appetite, and food intake after sleeve gastrectomy.American journal of physiology. Endocrinology and metabolism · 2024Trial
- Metabolic responses to exogenous ghrelin in obesity and early after Roux-en-Y gastric bypass in humans.Diabetes, obesity & metabolism · 2017Trial
- Acute administration of acyl, but not desacyl ghrelin, decreases blood pressure in healthy humans.European journal of endocrinology · 2017Trial
- Ghrelin Impairs Prandial Glucose Tolerance and Insulin Secretion in Healthy Humans Despite Increasing GLP-1.The Journal of clinical endocrinology and metabolism · 2016Trial
- Protective effects of ghrelin on pancreas in fructose diet and streptozotocin-induced diabetic rats.Journal of molecular histology · 2024Article
- Unacylated Ghrelin Protects Against Age-Related Loss of Muscle Mass and Contractile Dysfunction in Skeletal Muscle.Aging cell · 2024Article
- Regulation of peripheral tissue substrate metabolism by the gut-derived hormone ghrelin.Metabolism open · 2024Review
- Role of the Ghrelin System in Colorectal Cancer.International journal of molecular sciences · 2022Review
- Exocrine-Endocrine Crosstalk: The Influence of Pancreatic Cellular Communications on Organ Growth, Function and Disease.Frontiers in endocrinology · 2022Review
- Relationship Between Acyl and Desacyl Ghrelin Levels with Insulin Resistance and Body Fat Mass in Type 2 Diabetes Mellitus.Diabetes, metabolic syndrome and obesity : targets and therapy · 2022Article
- Exogenous Ghrelin Increases Plasma Insulin Level in Diabetic Rats.Biomolecules · 2020Article
- Acylated Ghrelin as a Multi-Targeted Therapy for Alzheimer's and Parkinson's Disease.Frontiers in neuroscience · 2020Review
- Glucose Homeostasis in Obese Women Is Not Associated to Unacylated Ghrelin Plasma Levels.Biomarker insights · 2020Article
- Ghrelin forms in the modulation of energy balance and metabolism.Eating and weight disorders : EWD · 2019Review
- Article
- Ghrelin regulation of glucose metabolism.Journal of neuroendocrinology · 2019Review
- Ghrelin's Relationship to Blood Glucose.Endocrinology · 2019Review
- Development and Characteristics of Pancreatic Epsilon Cells.International journal of molecular sciences · 2019Review
- Ghrelin regulation of glucose metabolism.Peptides · 2018Review
- Article
Corrections and comments
- Commented on by
Authors and funding
8 authors at 4 institutions in 2 countries.
Funding
Abstract
Unacylated ghrelin (UAG) is the predominant ghrelin isoform in the circulation. Despite its inability to activate the classical ghrelin receptor, preclinical studies suggest that UAG may promote β-cell function. We hypothesized that UAG would oppose the effects of acylated ghrelin (AG) on insulin secretion and glucose tolerance. AG (1 µg/kg/h), UAG (4 µg/kg/h), combined AG+UAG, or saline were infused to 17 healthy subjects (9 men and 8 women) on four occasions in randomized order. Ghrelin was infused for 30 min to achieve steady-state levels and continued through a 3-h intravenous glucose tolerance test. The acute insulin response to glucose (AIRg), insulin sensitivity index (SI), disposition index (DI), and intravenous glucose tolerance (kg) were compared for each subject during the four infusions. AG infusion raised fasting glucose levels but had no effect on fasting plasma insulin. Compared with the saline control, AG and AG+UAG both decreased AIRg, but UAG alone had no effect. SI did not differ among the treatments. AG, but not UAG, reduced DI and kg and increased plasma growth hormone. UAG did not alter growth hormone, cortisol, glucagon, or free fatty acid levels. UAG selectively decreased glucose and fructose consumption compared with the other treatments. In contrast to previous reports, acute administration of UAG does not have independent effects on glucose tolerance or β-cell function and neither augments nor antagonizes the effects of AG.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.